BUSINESS OBJECTIVES

---

SMARTECHS’ “platform technology” in the biopharma sector is protected with intellectual property (IP) patents that can enhance the pipeline and a wide range of Pharma R&D projects. 

SMARTECHS’ goal as a drug development company is to obtain FDA NDA approvals, then license its’ pipeline of prescription and OTC topical NSAIDs initially and then other drugs. Licenses can be non-exclusive or exclusive and can be global or for specific countries. Licensing can occur before or after any clinical milestone. 

SMARTECH’S targeted drug delivery technology applied to off-patent active pharmaceutical ingredient (API), initially NSAIDs, has demonstrated superior performance compared to existing formulations.